Condition
Visual Impairment Due to Diabetic Macular Edema
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 3 (1)
P 4 (2)
Trial Status
Withdrawn2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02878681Phase 4WithdrawnPrimary
24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
NCT02258009Phase 4WithdrawnPrimary
Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT01131585Phase 3TerminatedPrimary
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
Showing all 3 trials